There is an increased risk of preeclampsia among women infected with human immunodeficiency virus (HIV), and some of the risk may be linked to highly active antiretroviral therapy (HAART). This according to a 26-year, population-based, retrospective cohort study of 84,725 women in which HIV-infected pregnant women were compared with a HIV-negative comparison group. Primary outcome was incidence of preeclampsia. Researchers found:
• Of 453 HIV-infected women, 301 (66.4%) received HAART during pregnancy; 152 (33.6%) did not.
• HIV-infected women had a significantly higher risk of preeclampsia (10.2% vs 4.1%; adjusted OR=2.68), preeclampsia with severe features (4.0% vs 2.0%; aOR=2.03), early-onset (3.5% vs 1.4%, aOR=2.50), and late-onset preeclampsia (6.6% vs 2.6%; aOR=2.64), and pre-term birth at <37 weeks of gestation (11.0% vs 4.7%; aOR=2.50), compared with the comparison group.
• HIV-infected women who received HAART had a significantly higher risk of preeclampsia compared with women without HIV (13.0% vs 4.1%; aOR=3.52) and compared with the non-HAART group. (13.0% vs 4.6%; aOR=3.08).
• The non-HAART group had a similar risk compared with women without HIV.
Citation: Sansone M, Sarno L, Saccone G, et al. Risk of preeclampsia in human immunodeficiency virus-infected pregnant women. [Published online ahead of print May 4, 2016]. Obstet Gynecol. doi:10.1097/AOG.0000000000001424.
This Week's Must Reads
Must Reads in Gynecology
Management of Early Pregnancy Loss, Obstet Gynecol; ePub 2018 Nov; ACOG
ACOG: Well-Women Visits Can Minimize Health Risks, Obstet Gynecol; 2018 Oct; ACOG, et al